Clinical Profile of Nonalcoholic Fatty Liver Disease and Its Correlation with Metabolic Syndrome and Cardiovascular Risk

Overview

Journal Int J Appl Basic Med Res

Specialty General Medicine

Date 2024 Jan 17

PMID 38229733

Authors

Zahaan Vakil

Kiran Ahire

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) has been projected, within the next 20 years, to become the major cause of liver-related morbidity and mortality as well as a leading indication for liver transplantation. Affected South Asian Indians are at higher risk for the development of metabolic syndrome (MS), type 2 diabetes, and cardiovascular disease. There is a dearth of data related to NAFLD and its various sequelae and correlation with cardiovascular disease in South Asia.

Materials And Methods: It was an observational, prospective study conducted over 2 years on 80 patients in a tertiary care hospital in Mumbai. All patients diagnosed with NAFLD were investigated for MS according to the National Cholesterol Education Program Adult Treatment Panel III criteria, and a relationship between NAFLD and MS was correlated.

Results: MS was found to be present in 72.5% of the patients. Significant results were obtained while correlating MS parameters and fatty liver grading, implying that patients with a higher fatty liver grading were more likely to have derangements in metabolic markers.

Conclusion: NAFLD was found to be associated with an increased incidence of MS and thereby a higher risk of cardiovascular disease, warranting a high index of suspicion for both. A higher ultrasound grading of fatty liver was found to be associated with an increased incidence of MS.

References

Ferraioli G, Soares Monteiro L . Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol. 2019; 25(40):6053-6062. PMC: 6824276. DOI: 10.3748/wjg.v25.i40.6053. View

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

Petersen K, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C . Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A. 2006; 103(48):18273-7. PMC: 1693873. DOI: 10.1073/pnas.0608537103. View

Paschos P, Paletas K . Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009; 13(1):9-19. PMC: 2633261. View

Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate A, Rasciti L . Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004; 53(7):1020-3. PMC: 1774102. DOI: 10.1136/gut.2003.027086. View

Sung K, Wild S, Byrne C . Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol. 2014; 60(5):1040-5. DOI: 10.1016/j.jhep.2014.01.009. View

Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S . Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004; 19(8):854-8. DOI: 10.1111/j.1440-1746.2004.03312.x. View

Patel V, Sanyal A, Sterling R . Clinical Presentation and Patient Evaluation in Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016; 20(2):277-92. DOI: 10.1016/j.cld.2015.10.006. View

Sayiner M, Koenig A, Henry L, Younossi Z . Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016; 20(2):205-14. DOI: 10.1016/j.cld.2015.10.001. View

10.

Almeda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas C . Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol. 2009; 8 Suppl 1:S18-24. View

11.

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

12.

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

13.

Lazo M, Clark J . The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4):339-50. DOI: 10.1055/s-0028-1091978. View

14.

Perseghin G . The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig Dis. 2010; 28(1):210-3. DOI: 10.1159/000282088. View

15.

Bertot L, Adams L . The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016; 17(5). PMC: 4881593. DOI: 10.3390/ijms17050774. View

16.

Kanwar P, Kowdley K . The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis. 2016; 20(2):225-43. DOI: 10.1016/j.cld.2015.10.002. View

17.

Lum J, Cheah M, Leow W, Wan W, Lim T, Chow W . Clinical profile of non-alcoholic fatty liver disease in nonobese patients. J Gastroenterol Hepatol. 2020; 36(1):257-261. DOI: 10.1111/jgh.15154. View

18.

Galassi A, Reynolds K, He J . Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006; 119(10):812-9. DOI: 10.1016/j.amjmed.2006.02.031. View

19.

Duseja A . Nonalcoholic fatty liver disease in India - a lot done, yet more required!. Indian J Gastroenterol. 2010; 29(6):217-25. DOI: 10.1007/s12664-010-0069-1. View

20.

Amarapurkar D, Hashimoto E, Lesmana L, Sollano J, Chen P, Goh K . How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol. 2007; 22(6):788-93. DOI: 10.1111/j.1440-1746.2007.05042.x. View